Vessel Due F 250 #60

Vessel Due F instruction

Reed more and buy Vessel Due F here

Composition

A soft capsule in a gelatin shell contains 250 LE of active substance of sulodexide.
Additional components are: silicon dioxide (colloid form), sodium lauryl sarcosinate, triglycerides.
The shell consists of titanium dioxide, gelatin, red oxide Fe, sodium propyl parahydroxybenzoate, ethylparahydroxybenzoate and glycerol.
In 1 ampoule with a clear solution contains 600 le of active substance of sulodexide. Water and sodium chloride are used as auxiliary components.

Form of issue

Capsules and solution.
Red, gelatinous, soft oval-shaped capsules inside contain a white-gray suspension (an additional pink-cream shade is possible).
In a pack of cardboard there are 2 blisters (25 capsules each).
Transparent solution with yellow or light yellow in ampoules of 2 ml.
In a pack of cardboard 1 or 2 cells (5 ampoules each).

pharmachologic effect

Direct anticoagulant. The active ingredient is the natural component of Sulodexide, isolated and extracted from the mucous membrane of the small intestine of the pig.
The active component consists of two glycosaminoglycans: dermatan sulfate and heparin-like fraction.
The drug has the following effects:
    angioprotective;
    anticoagulant;
    profibrinolytic;
    antithrombotic.
Anticoagulant effect is manifested due to the affinity of heparin in cofactor-2, under the influence of which the thrombus is inactivated.
Antithrombotic effect provides increased secretion and synthesis of prostacyclin, suppression of active X factor, a decrease in the fibrinogen in the blood.
The prophibrinolytic effect is achieved by lowering the level of the inhibitor of the tissue activator of plasminogen and increasing the index of the activator in the blood.
The angioprotective effect is associated with the restoration of an adequate density of minus electric charge of the pores in the vascular basal membranes. In addition, the effect is provided by restoring the integrity of the vascular endothelial cells (functional and structural integrity).
Vessel Due F reduces the level of triglycerides, normalizing rheological blood counts. The active ingredient is able to stimulate lipoprotease (a specific lipolytic enzyme) that hydrolyses triglycerides that are part of the "bad" cholesterol.
With diabetic nephropathy, the active substance Sulodexide reduces the production of the extracellular matrix by suppressing the proliferation of mesangium cells; reduces the thickness of the basal membrane.

Pharmacodynamics and pharmacokinetics

Metabolized in the renal system and liver. The active substance does not undergo desulphation, in contrast to the low molecular weight forms of heparin and unfractionated heparin.
Desulphation inhibits antithrombotic activity and significantly accelerates the elimination process from the body.
The active component is absorbed in the lumen of the small intestine. 90% of the active substance is absorbed by the vascular endothelium. 4 hours after admission, Sulodexide is excreted from the body through the renal system.

Indications for use

    deep vein thrombosis, phlebopathy;
    pathology of cerebral circulation (acute period of stroke and recovery period);
    Angiopathy with a high risk of thrombogenesis (after myocardial infarction);
    dementia of vascular genesis;
    discirculatory form of encephalopathy caused by diabetes mellitus, total atherosclerosis, arterial hypertension;
    microangiopathy (retinopathy, nephropathy, neuropathy);
    occlusive lesions of peripherally located arteries (against diabetes mellitus and atherosclerosis);
    antiphospholipid syndrome, thrombolytic conditions (can be administered after low molecular weight heparin or together with Acetylsalicylic acid);
    macroangiopathic changes in patients with diagnosed diabetes mellitus (encephalopathy, diabetic foot syndrome, cardiopathy);
    therapy with thrombotic thrombocytopenia, induced by heparin.

Contraindications

    diseases accompanied by low blood coagulability;
    pregnancy, I trimester;
    individual hypersensitivity;
    hemorrhagic diathesis.

Side effects

    skin rashes;
    epigastric pain;
    vomiting;
    allergic responses;
    formation of a hematoma after administration of the solution;
    pain syndrome in the area of ​​injection;
    nausea;
    burning at the injection site.

Vessel Due F, instructions for use (Method and dosage)

In the first 15-20 days, the drug is administered parenterally. Intravenous and intramuscular injections are allowed. Intravenous administration may be a drop or bolus.
Scheme: 2 ml (600 LI - 1 ml) of the contents of the ampoule are dissolved in physiological saline with a volume of 200 ml. Upon completion of the injection therapy, they switch to taking the drug in capsule form for 30-40 days. Twice a day for 1 capsule. Preferred time is between meals.
It is recommended to take 2 courses a year. The instructions for Vessel Due F contain an indication of the possibility of changing the above-described treatment regimen, taking into account individual characteristics, tolerability, and other co-morbidities.

Overdose

In large doses, the drug can provoke bleeding and bleeding, which requires the abolition of the medication and conduction of the post-dandruff therapy.

Interaction

Significant interactions are not described. It is not allowed simultaneous therapy with antiplatelet agents and anticoagulants (according to the mechanism: direct and indirect).

Storage conditions

The drug is required to meet certain conditions: temperature regime - up to 30 degrees; away from sunlight.

Shelf life

Ampoules and capsules can be stored for 5 years without loss of effectiveness.

special instructions

Treatment requires mandatory control over all indicators of blood coagulogram analysis (antithrombin-2, APTT, clotting time, bleeding time).
The drug is able to increase the APTTV indicators in comparison with the initial ones by almost one and a half times. The drug does not affect the ability to drive.

Vessel Due F in pregnancy (and lactation)

The drug should not be administered in the first trimester of pregnancy. In the medical literature, a positive experience with the treatment of sulodexide in pregnant women with diagnosed Type I diabetes mellitus in the 2nd and 3rd trimesters has been described for the prevention of vascular pathology and for the registration of late toxicosis in pregnancy.
The medication can be used in the 2nd and 3rd trimesters under the supervision of the attending physician and with the consent of the obstetrician-gynecologist, vascular surgeon.
Data on the safety of Vessel Due F in lactation are not found in the relevant literature.

Reviews of Vessel Due F

The doctors' reviews confirm the high effectiveness of the drug in the therapy of thromboses and macroangiopathies. The drug has proven itself in the treatment of vascular complications in patients with diabetes mellitus.
Reviews on Vessel Due F during pregnancy: rarely causes a negative reaction, if used for the intended purpose, in accordance with the indicated treatment regimen.